花旗正密切关注Sora模型上线可能带来的影响，同时相信Vibes功能将朝拟真化方向演进。针对预计于 10月29日市后公布的第三季财报，产业调查显示随着新产品(如Business AI)陆续推出，Meta正持续争取 更多广告预算份额，据此花旗启动90日催化剂观察期。花旗维持Meta作为首选标的，重申"买入"评级及 目标价915美元。 花旗发表报告指，根据该行第三季对Reels的追踪，Meta广告载量按季增230个基点至27.1%(按年增460 个基点)，创自2022年第四季以来最大按季增幅(尽管第二季广告载量曾按季减少100个基点)。随着IG月 活跃用户于9月突破30亿，且Reels界面使当日发布影片曝光量提升50%，带动内容实时性显著增强，用 户参与度持续增长，花旗认为这将为提升广告投放精准度、相关性及个人化程度奠定良好基础。 ...

Core Viewpoint - ADMA Biologics and Grifols are prominent players in the plasma-derived therapies market, each with unique strengths and growth prospects, making stock selection challenging [1][2]. Company Overview ADMA Biologics - ADMA specializes in plasma-derived biologics for treating immune deficiencies and preventing infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [3][6]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes [4][5]. - The company anticipates significant revenue growth from Asceniv, driven by record demand and plans for a new R&D program, SG-001, which could generate $300-500 million in annual revenues [6]. Grifols - Grifols is a global leader in plasma-derived medicines, developing a wide range of biological therapies targeting various immunological conditions [7][8]. - The company reported sales of €7.2 billion in 2024, reflecting a 10.3% increase, and is recognized as the largest producer of A1PI [9][10]. - Grifols has a diverse portfolio and is positioned for consistent growth due to strong demand and operational execution [11]. Financial Estimates ADMA Biologics - The Zacks Consensus Estimate for ADMA's 2025 sales indicates an 18.61% year-over-year increase, with EPS expected to improve by 36.73% [12]. - Recent estimate revisions show a decline in EPS estimates for 2025 but an increase for 2026 [13]. Grifols - The Zacks Consensus Estimate for Grifols' 2025 sales suggests a 3.78% increase, with EPS expected to rise by 296% [12]. - EPS estimates for both 2025 and 2026 have seen upward revisions in the past 60 days [15]. Price Performance and Valuation - Year-to-date, ADMA shares have increased by 15.9%, outperforming Grifols' 10.6% rise, while the industry has declined by 4.1% [16]. - In terms of valuation, ADMA trades at 25.48X forward earnings, significantly higher than Grifols' 7.19X [16]. Investment Recommendation - ADMA shows steady growth driven by Asceniv demand, while Grifols, with a broader portfolio and better valuation, is considered a more favorable investment choice at present [20][21][22].